Octreotide Acetate for Injectable Suspension
Teva is recalling Octreotide Acetate 30 mg injection kits due to a lack of assurance of sterility.
Contact your healthcare provider or pharmacist if you have concerns about your medication. Do not use the affected product.
Why it was recalled
Teva Pharmaceuticals is recalling Octreotide Acetate for Injectable Suspension 30 mg kits due to a lack of assurance of sterility. The recall was initiated following quality system deficiencies identified at the contract manufacturing facility. This product was distributed nationwide.
Is mine affected?
Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
| Product | Strength | UPC | Recall # |
|---|---|---|---|
| Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mL vial of 30 mg strength, a pre-filled syringe containing 2 mL of diluent, one vial adapter, and one sterile 1¿ 19-gauge safety injection needle, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 69300 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054. NDC Kit Carton: 0480-9262-08; Vial Label: 0480-9260-01; Tray Label: 0480-9262-08; Di | – | 45011002 | D-0519-2026 |
| Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use | 30 mg | – | – |
Where it was sold
Distributed nationwide.
Official source
Other recent recalls from Teva Pharmaceuticals USA, Inc
Editorial summary by Recall Canary · last updated 2026-06-11 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification